The current research on PLEK2 has focused on head and neck squamous cell carcinoma, esophageal squamous cell carcinoma, gallbladder cancer, myeloproliferative neoplasms, gastric cancer, non-small cell lung cancer, and breast cancer. This evidence concerns the gene PLEK2 and non-small cell lung carcinoma.